Suven Life Sciences Ltd

NSE: SUVEN · BSE: 530239 · Healthcare · 30 announcements

Share price: ₹307.00
Market cap: ₹8,675 Cr
Revenue (annual): ₹7.11 Cr
Net profit (annual): ₹-276.3 Cr
P/E (TTM): -24.6×Sector 53.1×
Promoter holding: 65.47%-4.68% QoQ
FII holding: 0.48%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 1 Business Update 1 Annual General Meeting 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

3 Sep 2026 11:56 IST NSE

Business Update

Suven Life Sciences Business Update

Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.

clinical trial enrollment: 424.0 patients

Read the filing ↗

25 Aug 2026 18:24 IST NSE

Annual General Meeting

Suven Life Sciences Annual General Meeting

Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.

Read the filing ↗

11 Aug 2026 12:33 IST BSE

Other Announcement

Suven Life Sciences Other Announcement

Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.

Value: ₹857.6 Cr

Read the filing ↗